Clinical glycoproteomics: methods and diseases DOI Creative Commons
Yujia Wang,

Kaixin Lei,

Lijun Zhao

et al.

MedComm, Journal Year: 2024, Volume and Issue: 5(10)

Published: Oct. 1, 2024

Abstract Glycoproteins, representing a significant proportion of posttranslational products, play pivotal roles in various biological processes, such as signal transduction and immune response. Abnormal glycosylation may lead to structural functional changes glycoprotein, which is closely related the occurrence development diseases. Consequently, exploring protein can shed light on mechanisms behind disease manifestation pave way for innovative diagnostic therapeutic strategies. Nonetheless, study clinical glycoproteomics fraught with challenges due low abundance intricate structures glycosylation. Recent advancements mass spectrometry‐based have improved our ability identify abnormal glycoproteins samples. In this review, we aim provide comprehensive overview foundational principles recent glycoproteomic methodologies applications. Furthermore, discussed typical characteristics, underlying functions, diseases, brain cardiovascular cancers, kidney metabolic Additionally, highlighted potential avenues future glycoproteomics. These insights provided review will enhance comprehension methods diseases promote elucidation pathogenesis discovery novel biomarkers targets.

Language: Английский

Altered metabolism in cancer: insights into energy pathways and therapeutic targets DOI Creative Commons
Muhammad Tufail, Canhua Jiang, Ning Li

et al.

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: Sept. 18, 2024

Language: Английский

Citations

80
Multi-stage mechanisms of tumor metastasis and therapeutic strategies DOI Creative Commons
Zaoqu Liu, Jingqi Chen, Yuqing Ren

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Oct. 11, 2024

The cascade of metastasis in tumor cells, exhibiting organ-specific tendencies, may occur at numerous phases the disease and progress under intense evolutionary pressures. Organ-specific relies on formation pre-metastatic niche (PMN), with diverse cell types complex interactions contributing to this concept, adding a new dimension traditional cascade. Prior metastatic dissemination, as orchestrators PMN formation, primary tumor-derived extracellular vesicles prepare fertile microenvironment for settlement colonization circulating cells distant secondary sites, significantly impacting cancer progression outcomes. Obviously, solely intervening sites passively after macrometastasis is often insufficient. Early prediction holistic, macro-level control represent future directions therapy. This review emphasizes dynamic intricate systematic alterations that progresses, illustrates immunological landscape creation, deepens understanding treatment modalities pertinent metastasis, thereby identifying some prognostic predictive biomarkers favorable early predict occurrence design appropriate combinations.

Language: Английский

Citations

27
Energy metabolism in health and diseases DOI Creative Commons
Hui Liu, Shuo Wang, Jianhua Wang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2025, Volume and Issue: 10(1)

Published: Feb. 18, 2025

Language: Английский

Citations

15
Lung Cancer—Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature) DOI Open Access
Beata Smolarz,

H Łukasiewicz,

Dariusz Samulak

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(5), P. 2049 - 2049

Published: Feb. 26, 2025

Lung cancer is one of the most common malignant cancers in countries and leading cause death among diseases worldwide. Despite constant progress diagnosis therapy, survival rates patients diagnosed with lung remain unsatisfactory. Numerous epidemiological experimental studies conducted as early 1970s confirm that important risk factor for development long-term smoking, which remains valid to this day. In paper, authors present latest data on epidemiology, pathogenesis, treatment molecular aspects cancer. last decade, many alterations are effective have been discovered. adenocarcinoma, tyrosine kinase inhibitors were developed EGFR mutations ALK ROS1 translocations approved use advanced stage adenocarcinomas. case squamous cell carcinoma, evaluation these not yet being used clinical practice. addition, there ongoing concerning potential therapeutic targets, such ROS, MET, FGFR, DDR-2 RET. Constant diagnostic methods gives rise hopes an improved prognosis

Language: Английский

Citations

4
Microfluidic biosensors for biomarker detection in body fluids: a key approach for early cancer diagnosis DOI Creative Commons
Zhiting Liu, Yingyu Zhou, Jia Lü

et al.

Biomarker Research, Journal Year: 2024, Volume and Issue: 12(1)

Published: Dec. 5, 2024

Abstract Early detection of cancer significantly improves patient outcomes, with biomarkers offering a promising avenue for earlier and more precise diagnoses. Microfluidic biosensors have emerged as powerful tool detecting these in body fluids, providing enhanced sensitivity, specificity, rapid analysis. This review focuses on recent advances microfluidic from 2018 to 2024, detailing their operational principles, fabrication techniques, integration nanotechnology biomarker detection. Additionally, we reviewed innovations several aspects biosensors, such novel technologies, nanomaterials chip structures, which enhance capabilities. We highlight key pertinent early explore how biosensor technology contribute the evolving landscape personalized medicine. further technologies could be incorporated into clinical diagnostic workflows improve treatment outcomes. These help enable diagnostics. In addition, this addresses important issues enhancing scalability sensitivity settings points out future possibilities combining artificial intelligence diagnostics optimize practical applications. overview aims guide research applications by addressing current challenges identifying opportunities development field research.

Language: Английский

Citations

16
Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis DOI

Baofa Yu,

Wenxue Ma

Cytokine & Growth Factor Reviews, Journal Year: 2024, Volume and Issue: 79, P. 29 - 38

Published: Aug. 24, 2024

Language: Английский

Citations

14
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy DOI Creative Commons

Baofa Yu,

Shengwen Shao, Wenxue Ma

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: unknown, P. 217350 - 217350

Published: Nov. 1, 2024

Pancreatic cancer remains one of the most challenging malignancies to treat due its late-stage diagnosis, aggressive progression, and high resistance existing therapies. This review examines latest advancements in early detection, therapeutic strategies, with a focus on emerging biomarkers, tumor microenvironment (TME) modulation, integration artificial intelligence (AI) data analysis. We highlight promising including microRNAs (miRNAs) circulating DNA (ctDNA), that offer enhanced sensitivity specificity for early-stage diagnosis when combined multi-omics panels. A detailed analysis TME reveals how components such as cancer-associated fibroblasts (CAFs), immune cells, extracellular matrix (ECM) contribute therapy by creating immunosuppressive barriers. also discuss interventions target these components, aiming improve drug delivery overcome evasion. Furthermore, AI-driven analyses are explored their potential interpret complex data, enabling personalized treatment strategies real-time monitoring response. conclude identifying key areas future research, clinical validation regulatory frameworks AI applications, equitable access innovative comprehensive approach underscores need integrated, outcomes pancreatic cancer.

Language: Английский

Citations

14
Enhancing immuno-oncology investigations through multidimensional decoding of tumor microenvironment with IOBR 2.0 DOI Creative Commons
Dongqiang Zeng,

Yiran Fang,

Wenjun Qiu

et al.

Cell Reports Methods, Journal Year: 2024, Volume and Issue: unknown, P. 100910 - 100910

Published: Dec. 1, 2024

Language: Английский

Citations

13
Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment DOI Open Access
Pankaj Kumar Garg, Siddhika Pareek, Prakash Kulkarni

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(21), P. 6537 - 6537

Published: Oct. 30, 2024

Next-generation immunotherapies have revolutionized cancer treatment, offering hope for patients with hard-to-treat tumors. This review focuses on the clinical applications and advancements of key immune-based therapies, including immune checkpoint inhibitors, CAR-T cell therapy, new vaccines designed to harness system combat malignancies. A prime example is success pembrolizumab in treatment advanced melanoma, underscoring transformative impact these therapies. Combination treatments, integrating immunotherapy chemotherapy, radiation, targeted are demonstrating synergistic benefits improving patient outcomes. also explores evolving role personalized immunotherapy, guided by biomarkers, genomic data, tumor environment, better target individual Although significant progress has been made, challenges such as resistance, side effects, high costs persist. Technological innovations, nanotechnology artificial intelligence, explored future enablers The evaluates trials, breakthroughs, emerging immune-modulating agents delivery systems that hold great promise enhancing efficacy, reducing toxicity, expanding access immunotherapy. In conclusion, this highlights ongoing reshaping care, strategies poised overcome current further extend therapeutic reach.

Language: Английский

Citations

11
Single-cell transcriptomics unveils multifaceted immune heterogeneity in early-onset versus late-onset cervical cancer DOI Creative Commons
Qian Chen,

Dongfeng Deng,

Hong Zhu

et al.

World Journal of Surgical Oncology, Journal Year: 2025, Volume and Issue: 23(1)

Published: Jan. 14, 2025

Early-onset (EOCC) and late-onset cervical cancers (LOCC) represent two clinically distinct subtypes, each defined by unique clinical manifestations therapeutic responses. However, their immunological profiles remain poorly explored. Herein, we analyzed single-cell transcriptomic data from 4 EOCC LOCC samples to compare immune architectures. Epithelial cells in exhibited a notable dual phenotype, characterized immune-suppressive properties driven elevated CXCL production, alongside immune-stimulatory features linked heightened HLA molecule expression. CD4 + CD8 T demonstrated activation state, while NK diminished cytotoxicity. Macrophages displayed enhanced polarization towards both M1 M2 phenotypes, along with dendritic showing augmented antigen-presenting capacity. Regarding cancer-associated fibroblasts (CAFs), was enriched inflammatory CAFs, whereas harbored higher proportion of CAFs. These findings reveal the multifaceted heterogeneity between LOCC, underscoring imperative for age-tailored immunotherapeutic strategies.

Language: Английский

Citations

2